ATE73334T1 - Antioestrogenes arzneimittel zur perkutanen verabreichung. - Google Patents

Antioestrogenes arzneimittel zur perkutanen verabreichung.

Info

Publication number
ATE73334T1
ATE73334T1 AT85900469T AT85900469T ATE73334T1 AT E73334 T1 ATE73334 T1 AT E73334T1 AT 85900469 T AT85900469 T AT 85900469T AT 85900469 T AT85900469 T AT 85900469T AT E73334 T1 ATE73334 T1 AT E73334T1
Authority
AT
Austria
Prior art keywords
pct
drug
antioestrogenic
percutaneous administration
affections
Prior art date
Application number
AT85900469T
Other languages
English (en)
Inventor
Pierre Mauvais-Jarvis
Frederique Kuttenn
Original Assignee
Mauvais Jarvis Pierre
Frederique Kuttenn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mauvais Jarvis Pierre, Frederique Kuttenn filed Critical Mauvais Jarvis Pierre
Application granted granted Critical
Publication of ATE73334T1 publication Critical patent/ATE73334T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT85900469T 1984-01-20 1984-12-21 Antioestrogenes arzneimittel zur perkutanen verabreichung. ATE73334T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR8400927A FR2558373B1 (fr) 1984-01-20 1984-01-20 Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
EP85900469A EP0169214B1 (de) 1984-01-20 1984-12-21 Antiöstrogenes arzneimittel zur perkutanen verabreichung
PCT/EP1984/000436 WO1985003228A1 (fr) 1984-01-20 1984-12-21 Medicament antioestrogene pour administration percutanee

Publications (1)

Publication Number Publication Date
ATE73334T1 true ATE73334T1 (de) 1992-03-15

Family

ID=9300348

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85900469T ATE73334T1 (de) 1984-01-20 1984-12-21 Antioestrogenes arzneimittel zur perkutanen verabreichung.

Country Status (8)

Country Link
US (1) US4919937A (de)
EP (2) EP0151326B1 (de)
JP (1) JPH0667826B2 (de)
AT (1) ATE73334T1 (de)
DE (1) DE3485581D1 (de)
DK (1) DK155143C (de)
FR (1) FR2558373B1 (de)
WO (1) WO1985003228A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8604528D0 (en) * 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
DE69022722T2 (de) * 1989-03-10 1996-05-02 Endorecherche Inc Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen.
US5119827A (en) * 1990-09-05 1992-06-09 Board Of Regents, The University Of Texas System Mechanisms of antiestrogen resistance in breast cancer
US5518734A (en) * 1991-09-25 1996-05-21 Beta Pharmaceuticals Co. Transdermal delivery system for estradiol and process for manufacturing said device
US5705185A (en) * 1991-09-25 1998-01-06 Beta Pharmaceuticals Co. Transdermal delivery of estradiol and process for manufacturing said device
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
WO1997036570A1 (de) * 1996-03-29 1997-10-09 S.W. Patentverwertungs Ges. M.B.H. Edelsbacher U. Partner Kosmetikum bzw. kosmetikzusammensetzung zur glättung und straffung der haut bei gestörtem unterhaut-binde-fettgewebe, insbesondere bei der 'cellulite'
US20020086856A1 (en) 1998-03-18 2002-07-04 Alfred Schmidt Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor
EP0943333A1 (de) * 1998-03-18 1999-09-22 S.W. Patentverwertungs GmbH Medikament zur Prophylaxe und/oder Behandlung des Mammakarzinoms enthaltend einen Hemmer der Bildung von Oestrogenen
FI982733A (fi) * 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
US7863011B2 (en) * 2000-05-10 2011-01-04 Signe Biopharma, Inc. Screening method for predicting susceptibility to breast cancer
DE60143320D1 (de) 2000-05-10 2010-12-02 Signe Biopharma Inc Mittel und methoden für die diagnose, behandlung und vorbeugung von auf steroid hormone reagierende krebskrankheiten
US8119138B2 (en) * 2000-05-10 2012-02-21 Signe Biopharma Inc. Anti-estrogen and immune modulator combinations for treating breast cancer
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10054294A1 (de) * 2000-11-02 2002-05-16 Heinrich Wieland Topische Behandlung bei der Mastalgie
WO2003041654A2 (en) * 2001-11-14 2003-05-22 Sirbasku David A Anti-estrogen and immune modulator combinations for treating breast cancer
WO2003053292A1 (en) * 2001-12-20 2003-07-03 Femmepharma, Inc. Vaginal delivery of drugs
EP1952809B1 (de) * 2002-12-18 2017-08-02 Besins Healthcare Luxembourg SARL Formulierungen für die Reduzierung der Brustdichte mit 4-Hydroxi-Tamoxifen
JP4938237B2 (ja) * 2002-12-18 2012-05-23 ラボラトワール ブザン アンテルナスィヨナル ４−ヒドロキシタモキシフェンによる乳房痛の治療
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US7812010B2 (en) 2003-01-02 2010-10-12 Femmepharma, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
JP5490346B2 (ja) * 2003-04-01 2014-05-14 ブザン ヘルスケア ルクセンブルグ エスアーエールエル ４−ヒドロキシタモキシフェンによる乳癌の予防および治療
DE602004013439T2 (de) * 2003-06-09 2009-06-04 Ascend Therapeutics, Inc. Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen
EP1550440A1 (de) * 2003-12-15 2005-07-06 Laboratoires Besins International Verwendung von 4-hydroxytamoxifen zur Herstellung eines Arzneimittels zur Behandlung von Gynäkomastie
JP5069469B2 (ja) * 2003-12-15 2012-11-07 ラボラトワール ブザン アンテルナスィヨナル 女性化乳房治療用の薬剤を製造する際の４−ヒドロキシタモキシフェンの使用
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
AU2005227072B2 (en) * 2004-03-22 2010-08-19 Besins Healthcare Luxembourg Sarl Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (de) * 2004-03-22 2005-09-28 Laboratoires Besins International 4-Hydroxytamoxifen zur Behandlung von benignen Brusterkrankungen
DK1799201T3 (da) * 2004-10-14 2009-03-30 Besins Int Lab 4-Hydroxy-tamoxifen gelformuleringer
EP1647271A1 (de) * 2004-10-14 2006-04-19 Laboratoires Besins International Gelzubereitung enthaltend 4-Hydroxy tamoxifen.
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
DK1937276T3 (da) 2005-10-12 2013-02-11 Besins Healthcare Luxembourg Forbedret testosterongel og fremgangsmåde til anvendelse deraf
KR100850910B1 (ko) * 2006-12-22 2008-08-07 삼성전자주식회사 블루투스 디바이스를 연결하기 위한 장치 및 방법
CA2674078C (en) * 2006-12-26 2012-03-20 Femmepharma Holding Company, Inc. Topical administration of danazol
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
US11040019B2 (en) 2016-08-19 2021-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002097B1 (de) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalken-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
FR2515041A1 (fr) * 1981-10-26 1983-04-29 Besins Jean Medicament a base de progesterone pour le traitement des affections mammaires

Also Published As

Publication number Publication date
WO1985003228A1 (fr) 1985-08-01
EP0151326A1 (de) 1985-08-14
DK155143B (da) 1989-02-20
US4919937A (en) 1990-04-24
DK420385A (da) 1985-09-17
DE3485581D1 (de) 1992-04-16
EP0169214A1 (de) 1986-01-29
JPH0667826B2 (ja) 1994-08-31
FR2558373A1 (fr) 1985-07-26
DK155143C (da) 1989-07-03
JPS61500914A (ja) 1986-05-08
DK420385D0 (da) 1985-09-17
EP0151326B1 (de) 1989-07-12
EP0169214B1 (de) 1992-03-11
FR2558373B1 (fr) 1987-07-03

Similar Documents

Publication Publication Date Title
ATE73334T1 (de) Antioestrogenes arzneimittel zur perkutanen verabreichung.
CA2068324A1 (en) Metal-peptide compositions and methods for stimulating hair growth
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE3860043D1 (de) Verwendung von biertreberextrakt zur herstellung von medizinischen und kosmetischen zubereitungen.
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
ATE17079T1 (de) Praeparat zur behandlung von wunden der hautoberflaeche und verfahren zur herstellung des praeparats.
EG20001A (en) Process for preparing of novel hydrox-amic acid and N-hydroxyurea derivatives and their use
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ES482723A1 (es) Un procedimiento para la obtencion de una composicion de clotrimazol
EP0009688A3 (en) Medicated animal food based on liver powder, process for its preparation and its use in combating animal diseases
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
IS1565B (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
ES2010561A6 (es) Procedimiento para preparar una composicion farmaceutica a base de un analogo de somatostatina.
NO166939C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive carboxylsyrederivater.
ES478967A1 (es) Un procedimiento para preparar compuestos de acido 3-cefem-4-carboxilico disustituido en las posiciones 3 y 7.
FR2731907B1 (fr) Composition dermatologique et/ou cosmetique depigmentante et utilisation dans une methode cosmetique
ATE302594T1 (de) Zubereitungen zur aknebehandlung
ATE193651T1 (de) Therapeutisches system zur behandlung der psoriasis
ATE223721T1 (de) Edelfosin zur behandlung von hirntumoren
BR8008818A (pt) Peptidos farmacologicamente ativos e medicamentos contendo os mesmos
IE45054L (en) Veterinary composition
US2937974A (en) Process for preparing a modified lactalbumin hydrolysate
ES2006121A6 (es) Procedimiento para la preparacion de una composicion farmaceutica destinada al tratamiento de enfermedades cutaneas.
ATE143946T1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
Hare et al. Acrodermatitis enteropathica

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time